

# Christophe Bauters

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1566056/publications.pdf>

Version: 2024-02-01

188  
papers

8,376  
citations

47006

47  
h-index

51608

86  
g-index

196  
all docs

196  
docs citations

196  
times ranked

8528  
citing authors

#	ARTICLE	IF	CITATIONS
1	Compared impact of diabetes on the risk of heart failure from acute myocardial infarction to chronic coronary artery disease. <i>Diabetes and Metabolism</i> , 2022, 48, 101265.	2.9	3
2	Clinical significance of myocardial work parameters after acute myocardial infarction. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	6
3	Diabetes mellitus and cardiovascular mortality across the spectrum of aortic stenosis. <i>Heart</i> , 2022, 108, 1815-1821.	2.9	6
4	Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 287-294.	4.0	3
5	Relative Importance of Heart Failure Events Compared to Stroke and Bleeding in AF Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 923.	2.4	3
6	Very long-term outcomes of older adults with stable coronary artery disease (from the CORONOR) <i>Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50</i>	0.7	1
7	Association of Mortality With Aortic Stenosis Severity in Outpatients. <i>JAMA Cardiology</i> , 2021, 6, 1424.	6.1	20
8	Management of antithrombotics in situations with a gap in evidence: A national French survey focusing on patients with coronary artery disease and atrial fibrillation. <i>International Journal of Cardiology</i> , 2021, , .	1.7	0
9	Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 788-801.	1.0	7
10	Real-Life Incident Atrial Fibrillation in Outpatients with Coronary Artery Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 2367.	2.4	4
11	Apolipoprotein Proteomic Profiling for the Prediction of Cardiovascular Death in Patients with Heart Failure. <i>Proteomics - Clinical Applications</i> , 2020, 14, 2000035.	1.6	2
12	Secondary prevention and outcomes in outpatients with coronary artery disease, atrial fibrillation or heart failure: a focus on disease overlap. <i>Open Heart</i> , 2020, 7, e001165.	2.3	8
13	Gender differences in clinical characteristics, medical management, risk factor control, and long-term outcome of patients with stable coronary artery disease: from the CORONOR registry. <i>Panminerva Medica</i> , 2020, 61, 432-438.	0.8	2
14	Relative impact of bleedings over ischaemic events in patients with heart failure: insights from the CARDIONOR registry. <i>ESC Heart Failure</i> , 2020, 7, 3821-3829.	3.1	3
15	Letter by Pinet et al Regarding Article, "Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury" <i>Circulation Research</i> , 2019, 125, e20-e21.	4.5	2
16	Increased clusterin levels after myocardial infarction is due to a defect in protein degradation systems activity. <i>Cell Death and Disease</i> , 2019, 10, 608.	6.3	10
17	Five-Year Risk of Major Ischemic and Hemorrhagic Events After Intracerebral Hemorrhage. <i>Stroke</i> , 2019, 50, 1100-1107.	2.0	74
18	Integrative System Biology Analyses Identify Seven MicroRNAs to Predict Heart Failure. <i>Non-coding RNA</i> , 2019, 5, 22.	2.6	9

#	ARTICLE	IF	CITATIONS
19	Circulating proteomic signature of early death in heart failure patients with reduced ejection fraction. <i>Scientific Reports</i> , 2019, 9, 19202.	3.3	21
20	Echocardiographic diastolic function evolution in patients with an anterior $Q$ -wave myocardial infarction: insights from the REVE $2$ study. <i>ESC Heart Failure</i> , 2019, 6, 70-79.	3.1	4
21	Additional diagnostic value of new CT imaging techniques for the functional assessment of coronary artery disease: a meta-analysis. <i>European Radiology</i> , 2019, 29, 3044-3061.	4.5	20
22	Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5-Year CORONOR Registry. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	10
23	Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 634-643.	1.6	8
24	First Hospitalization for Heart Failure in Outpatients With Stable Coronary Artery Disease: Determinants, Role of Incident Myocardial Infarction, and Prognosis. <i>Journal of Cardiac Failure</i> , 2018, 24, 815-822.	1.7	24
25	Incidence and determinants of cerebrovascular events in outpatients with stable coronary artery disease. <i>European Stroke Journal</i> , 2018, 3, 272-280.	5.5	7
26	Elective Coronary Revascularization Procedures in Patients With Stable Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 868-875.	2.9	7
27	Accuracy of cardiac magnetic resonance imaging to rule out significant coronary artery disease in patients with systolic heart failure of unknown aetiology: Single-centre experience and comprehensive meta-analysis. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 686-701.	1.6	5
28	Expression and Implication of Clusterin in Left Ventricular Remodeling After Myocardial Infarction. <i>Circulation: Heart Failure</i> , 2018, 11, e004838.	3.9	21
29	Angiotensin II receptor blockers versus angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: Prevalence, correlates, and prognostic impact (from the CORONOR) <i>Tj ETQq1 1 0.784314 rgBf /Overlo</i>		
30	Evaluation of screening for myocardial ischaemia in women at cardiovascular risk. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 379-388.	1.6	1
31	Integrative network analysis reveals time-dependent molecular events underlying left ventricular remodeling in post-myocardial infarction patients. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 1445-1453.	3.8	3
32	Incident Myocardial Infarction and Very Late Stent Thrombosis in Outpatients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2149-2156.	2.8	35
33	Long-term risk and predictors of cardiovascular death in stable coronary artery disease. <i>Coronary Artery Disease</i> , 2017, 28, 636-641.	0.7	30
34	Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. <i>Clinical Cardiology</i> , 2017, 40, 932-939.	1.8	43
35	MicroRNAs regulating superoxide dismutase 2 are new circulating biomarkers of heart failure. <i>Scientific Reports</i> , 2017, 7, 14747.	3.3	32
36	Effect of left ventricular systolic dysfunction on secondary medical prevention and clinical outcome in stable coronary artery disease patients. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 35-41.	1.6	4

#	ARTICLE	IF	CITATIONS
37	Long-term prognostic impact of left ventricular remodeling after a first myocardial infarction in modern clinical practice. PLoS ONE, 2017, 12, e0188884.	2.5	29
38	Incidence and timing of left ventricular reverse remodeling: Key information for the management of patients with new onset left ventricular systolic dysfunction. International Journal of Cardiology, 2016, 214, 518-519.	1.7	1
39	Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). Cardiology, 2016, 134, 11-18.	1.4	8
40	Screening for asymptomatic coronary artery disease in patients with diabetes mellitus: A systematic review and meta-analysis of randomized trials. BMC Cardiovascular Disorders, 2016, 16, 90.	1.7	11
41	Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 1557-1571.	2.8	99
42	A systematic review and meta-regression of temporal trends in the excess mortality associated with diabetes mellitus after myocardial infarction. International Journal of Cardiology, 2016, 217, 109-121.	1.7	37
43	MicroRNAs as Circulating Biomarkers of Left Ventricular Remodeling after Myocardial Infarction. Cardiology, 2016, 133, 262-263.	1.4	2
44	Effect of aspirin in addition to oral anticoagulants in stable coronary artery disease outpatients with an indication for anticoagulation. Panminerva Medica, 2016, 58, 271-285.	0.8	7
45	Practice Patterns for Outpatients With Stable Coronary Artery Disease: A Case Vignette-based Survey Among French Cardiologists. EBioMedicine, 2015, 2, 1662-1668.	6.1	5
46	Multimarker Proteomic Profiling for the Prediction of Cardiovascular Mortality in Patients with Chronic Heart Failure. PLoS ONE, 2015, 10, e0119265.	2.5	15
47	Secondary medical prevention and clinical outcome in coronary artery disease patients with a history of non-coronary vascular intervention: A report from the CORONOR investigators. European Journal of Preventive Cardiology, 2015, 22, 864-871.	1.8	7
48	Copeptin in acute coronary syndromes and heart failure management: State of the art and future directions. Archives of Cardiovascular Diseases, 2015, 108, 398-407.	1.6	25
49	Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease. Archives of Cardiovascular Diseases, 2015, 108, 340-346.	1.6	7
50	Dual antiplatelet therapy in patients with a long coronary artery lesion over 30mm: Determinants and impact on prognosis. Archives of Cardiovascular Diseases, 2015, 108, 235-243.	1.6	6
51	Antithrombotic therapy in diabetic patients with coronary artery disease. Panminerva Medica, 2015, 57, 87-99.	0.8	4
52	Prognostic impact of Æ-blocker use in patients with stable coronary artery disease. Heart, 2014, 100, 1757-1761.	2.9	29
53	Prognosis of Patients With Stable Coronary Artery Disease (from the CORONOR Study). American Journal of Cardiology, 2014, 113, 1142-1145.	1.6	88
54	Long-Term Functional and Clinical Follow-Up of Patients With Heart Failure With Recovered Left Ventricular Ejection Fraction After Î²-Blocker Therapy. Circulation: Heart Failure, 2014, 7, 434-439.	3.9	78

#	ARTICLE	IF	CITATIONS
55	Circulating Long Noncoding RNA, LIPCAR, Predicts Survival in Patients With Heart Failure. <i>Circulation Research</i> , 2014, 114, 1569-1575.	4.5	542
56	Incidence, Source, Determinants, and Prognostic Impact of Major Bleeding in Outpatients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1430-1436.	2.8	91
57	Poor agreement between light transmission aggregometry, Verify Now P2Y12 and vasodilator-stimulated phosphoprotein for clopidogrel low-response assessment: A potential explanation of negative results of recent randomized trials. <i>Platelets</i> , 2014, 25, 499-505.	2.3	25
58	Dual antiplatelet therapy in patients with stable coronary artery disease in modern practice: Prevalence, correlates, and impact on prognosis (from the Suivi d'une cohorte de patients) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 61</i>	1.6	10
59	Two-year outcome of patients after a first hospitalization for heart failure: A national observational study. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 158-168.	1.6	81
60	Heart omics in AGEing (HOMAGE): design, research objectives and characteristics of the common database. <i>Journal of Biomedical Research</i> , 2014, 28, 349.	1.6	24
61	B-type natriuretic peptide for the prediction of left ventricular remodelling. <i>Cardiovascular Journal of Africa</i> , 2014, 25, 33, 39.	0.4	0
62	First hospitalization for heart failure in France in 2009: Patient characteristics and 30-day follow-up. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 570-585.	1.6	65
63	Impact of initial clinical presentation on clopidogrel low response. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 593-600.	1.6	1
64	Long-term prognostic value of preprocedural adiponectin levels in patients undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2013, 168, 4921-4924.	1.7	3
65	Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 168, 1837-1840.	1.7	94
66	New technologies, new therapies: toward personalized medicine in heart failure patients?. <i>European Heart Journal</i> , 2013, 34, 636-637.	2.2	5
67	Extracellular Matrix Turnover Biomarkers Predict Long-Term Left Ventricular Remodeling After Myocardial Infarction. <i>Circulation: Heart Failure</i> , 2013, 6, 1199-1205.	3.9	34
68	Right Ventricular Systolic Function in Organic Mitral Regurgitation. <i>Circulation</i> , 2013, 127, 1597-1608.	1.6	83
69	Serum MMP-8: A Novel Indicator of Left Ventricular Remodeling and Cardiac Outcome in Patients after Acute Myocardial Infarction. <i>PLoS ONE</i> , 2013, 8, e71280.	2.5	39
70	Right ventricular systolic function for risk stratification in patients with stable left ventricular systolic dysfunction: comparison of radionuclide angiography to echoDoppler parameters. <i>European Heart Journal</i> , 2012, 33, 2672-2679.	2.2	42
71	Cardiac remodeling and heart failure after a first anterior myocardial infarction in patients with diabetes mellitus. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 353-359.	1.5	24
72	Circulating levels of soluble Fas ligand and left ventricular remodeling after acute myocardial infarction (from the REVE-2 study). <i>Journal of Cardiology</i> , 2012, 60, 93-97.	1.9	9

#	ARTICLE	IF	CITATIONS
73	Incidence, determinants and consequences of left atrial remodelling after a first anterior myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 18-23.	1.6	3
74	Usefulness of Circulating Biomarkers for the Prediction of Left Ventricular Remodeling After Myocardial Infarction. <i>American Journal of Cardiology</i> , 2012, 110, 277-283.	1.6	55
75	White blood cell and peripheral blood mononuclear cell counts for the prediction of left ventricular remodeling after myocardial infarction. <i>Journal of Cardiology</i> , 2011, 58, 197-198.	1.9	4
76	Cardiovascular proteomics: Translational studies to develop novel biomarkers in heart failure and left ventricular remodeling. <i>Proteomics - Clinical Applications</i> , 2011, 5, 57-66.	1.6	24
77	Strategy for purification and mass spectrometry identification of SELDI peaks corresponding to low-abundance plasma and serum proteins. <i>Journal of Proteomics</i> , 2011, 74, 420-430.	2.4	11
78	Circulating levels of hepatocyte growth factor and left ventricular remodelling after acute myocardial infarction (from the REVE-2 study). <i>European Journal of Heart Failure</i> , 2011, 13, 1314-1322.	7.1	20
79	Decreased Serine207 phosphorylation of troponin T as a biomarker for left ventricular remodelling after myocardial infarction. <i>European Heart Journal</i> , 2011, 32, 115-123.	2.2	30
80	Dosing Strategies for Antiplatelet Therapy in Percutaneous Coronary Intervention. <i>Hospital Practice (1995)</i> , 2010, 38, 50-58.	1.0	2
81	Left Ventricular Remodeling and Heart Failure After Myocardial Infarction in Elderly Patients. <i>American Journal of Cardiology</i> , 2010, 105, 903-904.	1.6	1
82	Usefulness of Serial Assessment of B-Type Natriuretic Peptide, Troponin I, and C-Reactive Protein to Predict Left Ventricular Remodeling After Acute Myocardial Infarction (from the REVE-2 Study). <i>American Journal of Cardiology</i> , 2010, 106, 1410-1416.	1.6	84
83	Impact of thrombus aspiration use and direct stenting on final myocardial blush score in patients presenting with ST-elevation myocardial infarction. <i>Cardiovascular Revascularization Medicine</i> , 2010, 11, 149-154.	0.8	4
84	Deep plasma proteomic analysis of patients with left ventricular remodeling after a first myocardial infarction. <i>Proteomics - Clinical Applications</i> , 2010, 4, 654-673.	1.6	31
85	Hybrid revascularization, comprising coronary artery bypass graft with exclusive arterial conduits followed by early drug-eluting stent implantation, in multivessel coronary artery disease. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 502-511.	1.6	27
86	Late recovery in left ventricular systolic function after discharge of patients with a first anterior myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 538-545.	1.6	12
87	Prospective assessment of multiple cardiac papillary fibroelastomas. <i>International Journal of Cardiology</i> , 2010, 145, 319-320.	1.7	1
88	Response to Letter Regarding Article, "Functional Impairment of von Willebrand Factor in Hypertrophic Cardiomyopathy: Relation to Rest and Exercise Obstruction". <i>Circulation</i> , 2009, 119, .	1.6	0
89	Association of Ornithine Transcarbamylase Gene Polymorphisms With Hypertension and Coronary Artery Vasomotion. <i>American Journal of Hypertension</i> , 2009, 22, 993-1000.	2.0	9
90	Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2009, 10, 144-150.	0.8	21

#	ARTICLE	IF	CITATIONS
91	Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome. <i>American Heart Journal</i> , 2009, 157, 375-382.	2.7	45
92	Predicting left ventricular remodeling after a first myocardial infarction by plasma proteome analysis. <i>Proteomics</i> , 2008, 8, 1798-1808.	2.2	27
93	High incidence of recurrent in stent thrombosis after successful treatment of a first in stent thrombosis. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 470-478.	1.7	25
94	Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. <i>European Radiology</i> , 2008, 18, 2765-2769.	4.5	79
95	Cardiac Correlates of Exercise Induced Pulmonary Hypertension in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction. <i>Echocardiography</i> , 2008, 25, 386-393.	0.9	18
96	Exercise does not enhance the prognostic value of Doppler echocardiography in patients with left ventricular systolic dysfunction and functional mitral regurgitation at rest. <i>American Heart Journal</i> , 2008, 155, 752-757.	2.7	30
97	High-sensitivity C-reactive protein for risk stratification in patients with heart failure. <i>American Heart Journal</i> , 2008, 155, e7.	2.7	0
98	Left ventricular remodeling is associated with the severity of mitral regurgitation after inaugural anterior myocardial infarction. Optimal timing for echocardiographic imaging. <i>American Heart Journal</i> , 2008, 155, 959-965.	2.7	20
99	Left Ventricular Abnormal Response During Dynamic Exercise in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction at Rest. <i>Journal of Cardiac Failure</i> , 2008, 14, 475-480.	1.7	82
100	The effect of ageing on cardiac remodelling and hospitalization for heart failure after an inaugural anterior myocardial infarction. <i>European Heart Journal</i> , 2008, 29, 1992-1999.	2.2	12
101	Prognostic importance of tissue Doppler-derived diastolic function in patients presenting with acute coronary syndrome: a bedside echocardiographic study. <i>European Journal of Echocardiography</i> , 2008, 9, 594-598.	2.3	26
102	Functional Impairment of Von Willebrand Factor in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2008, 118, 1550-1557.	1.6	54
103	Polyarteritis nodosa-related coronary aneurysms. <i>Journal of Rheumatology</i> , 2008, 35, 933-4.	2.0	4
104	Association of OAZ1 Gene Polymorphisms With Subclinical and Clinical Vascular Events. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2120-2126.	2.4	9
105	Myocardial metastasis of a bronchial carcinoid. <i>European Heart Journal</i> , 2007, 28, 391-391.	2.2	7
106	The consensus is clearly needed for the definition of stress hyperglycaemia in acute myocardial infarction: reply. <i>European Heart Journal</i> , 2007, 28, 2042-2043.	2.2	4
107	A prospective evaluation of left ventricular remodeling after inaugural anterior myocardial infarction as a function of gene polymorphisms in the renin-angiotensin-aldosterone, adrenergic, and metalloproteinase systems. <i>American Heart Journal</i> , 2007, 153, 641-648.	2.7	27
108	The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure. A study on 686 consecutive patients. <i>American Heart Journal</i> , 2007, 153, e15.	2.7	7



#	ARTICLE	IF	CITATIONS
109	The effects of $\beta$ -blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. <i>American Heart Journal</i> , 2007, 154, 589-595.	2.7	36
110	Relation of Admission White Blood Cell Count to Left Ventricular Remodeling After Anterior Wall Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2007, 100, 182-184.	1.6	17
111	Prevalence and Determinants of Cognitive Impairment in Chronic Heart Failure Patients. <i>Congestive Heart Failure</i> , 2007, 13, 205-208.	2.0	58
112	Prospective Aortic Screening in Men With Coronary Aneurysms. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1227-1229.	2.8	15
113	The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: A study in 686 consecutive patients. <i>American Heart Journal</i> , 2006, 152, 736-741.	2.7	28
114	Left Ventricular Remodeling After Anterior Wall Acute Myocardial Infarction in Modern Clinical Practice (from the REmodelage VEentriculaire [REVE] Study Group). <i>American Journal of Cardiology</i> , 2006, 98, 1144-1149.	1.6	167
115	An unusual case of papillary fibroelastoma "invading" the mitral valve. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 132, 1472-1473.	0.8	5
116	Myocardial asynchronism is a determinant of changes in functional mitral regurgitation severity during dynamic exercise in patients with chronic heart failure due to severe left ventricular systolic dysfunction. <i>European Heart Journal</i> , 2006, 27, 679-683.	2.2	54
117	Stress hyperglycaemia is an independent predictor of left ventricular remodelling after first anterior myocardial infarction in non-diabetic patients. <i>European Heart Journal</i> , 2006, 28, 546-552.	2.2	36
118	Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 137-142.	1.5	113
119	Nature of coronary disease in patients with insulin resistance and its impact on revascularization strategies. <i>Coronary Artery Disease</i> , 2005, 16, 481-487.	0.7	2
120	The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure*. <i>European Journal of Heart Failure</i> , 2005, 7, 966-973.	7.1	57
121	High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. <i>European Heart Journal</i> , 2005, 26, 2245-2250.	2.2	76
122	Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization. <i>European Heart Journal</i> , 2005, 26, 2387-2395.	2.2	29
123	Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure. <i>American Heart Journal</i> , 2005, 150, 137-143.	2.7	44
124	Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. <i>European Heart Journal</i> , 2004, 25, 656-662.	2.2	159
125	Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. <i>European Heart Journal</i> , 2004, 25, 688-693.	2.2	80
126	Protective Effects of Basic Fibroblast Growth Factor in Early Atherosclerosis. <i>Growth Factors</i> , 2004, 22, 157-167.	1.7	12



#	ARTICLE	IF	CITATIONS
127	B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1584-1589.	2.8	122
128	Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2004, 6, 17-21.	7.1	26
129	Is hormonal activation during exercise useful for risk stratification in patients with moderate congestive heart failure?. <i>American Heart Journal</i> , 2004, 148, 349-355.	2.7	17
130	Angioplasty in the diabetic patient. <i>Journal of Invasive Cardiology</i> , 2004, 16, 23-7.	0.4	2
131	Influence of diabetes mellitus on heart failure risk and outcome. <i>Cardiovascular Diabetology</i> , 2003, 2, 1.	6.8	163
132	Angiotensin Converting Enzyme and Angiotensin II Type 1 Receptor Polymorphisms in Patients with Coronary Aneurysms. <i>Thrombosis Journal</i> , 2003, 1, 5.	2.1	3
133	Aspirin Does Not Adversely Affect Survival in Patients With Stable Congestive Heart Failure Treated With Angiotensin-Converting Enzyme Inhibitors. <i>Chest</i> , 2003, 124, 1250-1258.	0.8	24
134	Coronary Thrombosis and Myocardial Bridging. <i>Circulation</i> , 2002, 105, 130-130.	1.6	39
135	Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2002, 40, 43-48.	2.8	208
136	effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. <i>Journal of the American College of Cardiology</i> , 2002, 40, 410-417.	2.8	112
137	Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2001, 357, 1321-1324.	13.7	93
138	Restenotic process and DD genotype after angiotensin-converting enzyme inhibitor treatment. <i>Lancet, The</i> , 2001, 358, 758-759.	13.7	1
139	Patency of Percutaneous Transluminal Coronary Angioplasty Sites at 6-Month Angiographic Follow-Up. <i>Circulation</i> , 2001, 103, 1218-1224.	1.6	113
140	Gene Polymorphisms and Outcome After Coronary Angioplasty. <i>Current Interventional Cardiology Reports</i> , 2001, 3, 281-286.	0.4	2
141	Paraoxonase Polymorphism (Gln192Arg) as a Determinant of the Response of Human Coronary Arteries to Serotonin. <i>Circulation</i> , 2000, 101, 740-743.	1.6	24
142	Basic Fibroblast Growth Factor Increases Tissue Factor Expression in Circulating Monocytes and in Vascular Wall. <i>Circulation</i> , 2000, 101, 2000-2006.	1.6	22
143	The French randomized optimal stenting trial: a prospective evaluation of provisional stenting guided by coronary velocity reserve and quantitative coronary angiography. <i>Journal of the American College of Cardiology</i> , 2000, 36, 404-409.	2.8	44
144	Cytomegalovirus Infection and Coronary Restenosis. <i>Circulation</i> , 1999, 99, 1278-1279.	1.6	11

#	ARTICLE	IF	CITATIONS
145	Angiographically Documented Late Reocclusion After Successful Coronary Angioplasty of an Infarct-Related Lesion Is a Powerful Predictor of Long-Term Mortality. <i>Circulation</i> , 1999, 99, 2243-2250.	1.6	28
146	Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling. <i>Journal of the American College of Cardiology</i> , 1999, 33, 876-882.	2.8	63
147	Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. <i>Journal of the American College of Cardiology</i> , 1999, 34, 476-485.	2.8	82
148	Dual Determination of Angiotensin-Converting Enzyme and Angiotensin-II Type 1 Receptor Genotypes as Predictors of Restenosis After Coronary Angioplasty. <i>American Journal of Cardiology</i> , 1998, 81, 79-81.	1.6	31
149	Predictors of Restenosis After Coronary Stent Implantation. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1291-1298.	2.8	239
150	Six-Month Angiographic Outcome After Successful Repeat Percutaneous Intervention for In-Stent Restenosis. <i>Circulation</i> , 1998, 97, 318-321.	1.6	175
151	Enhanced Monocyte Tissue Factor Response After Experimental Balloon Angioplasty in Hypercholesterolemic Rabbit: Inhibition With Dietary L-Arginine. <i>Circulation</i> , 1998, 98, 1776-1782.	1.6	41
152	Coronary Angioscopic Findings in the Infarct-Related Vessel Within 1 Month of Acute Myocardial Infarction. <i>Circulation</i> , 1998, 97, 26-33.	1.6	150
153	Intramural Injection of Biodegradable Microspheres as a Local Drug-Delivery System to Inhibit Neointimal Thickening in a Rabbit Model of Balloon Angioplasty. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, 513-519.	1.9	15
154	ACE Inhibition Accelerates Endothelial Regrowth in Vivo: A Possible Explanation for the Benefit Observed with ACE Inhibitors Following Arterial Injury. <i>Biochemical and Biophysical Research Communications</i> , 1997, 231, 577-581.	2.1	16
155	The Angiotensin II Type 1 Receptor Gene Polymorphism Is Associated With Coronary Artery Vasoconstriction. <i>Journal of the American College of Cardiology</i> , 1997, 29, 486-490.	2.8	107
156	Growth Factors as a Potential New Treatment for Ischemic Heart Disease. <i>Clinical Cardiology</i> , 1997, 20, 11-52.	1.8	7
157	Prevention of Restenosis. <i>Trends in Cardiovascular Medicine</i> , 1997, 7, 90-94.	4.9	6
158	Effects of Stenting of Recent or Chronic Coronary Occlusions on Late Vessel Patency and Left Ventricular Function. <i>American Journal of Cardiology</i> , 1997, 80, 1150-1154.	1.6	30
159	D Allele of the Angiotensin Converting Enzyme Is a Major Risk Factor for Restenosis After Coronary Stenting. <i>Circulation</i> , 1997, 96, 56-60.	1.6	127
160	Restenosis Rates in Diabetic Patients. <i>Circulation</i> , 1997, 96, 1454-1460.	1.6	222
161	Hypercholesterolemia Attenuates Angiogenesis but Does Not Preclude Augmentation by Angiogenic Cytokines. <i>Circulation</i> , 1997, 96, 2667-2674.	1.6	155
162	Effects of Coronary Stenting on Restenosis and Occlusion After Angioplasty of the Culprit Vessel in Patients With Recent Myocardial Infarction. <i>Circulation</i> , 1997, 96, 2854-2858.	1.6	32

#	ARTICLE	IF	CITATIONS
163	Therapeutic Angiogenesis Following Arterial Gene Transfer of Vascular Endothelial Growth Factor in a Rabbit Model of Hindlimb Ischemia. <i>Biochemical and Biophysical Research Communications</i> , 1996, 227, 628-635.	2.1	157
164	ACE Polymorphism, a Genetic Predictor of Occlusion After Coronary Angioplasty. <i>American Journal of Cardiology</i> , 1996, 78, 679-681.	1.6	14
165	Basic Fibroblast Growth Factor Restores Endothelium-Dependent Responses After Balloon Injury of Rabbit Arteries. <i>Circulation</i> , 1996, 93, 18-22.	1.6	32
166	Two-pronged antiplatelet therapy with aspirin and ticlopidine without systemic anticoagulation. <i>Coronary Artery Disease</i> , 1995, 6, 341-346.	0.7	29
167	Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. <i>Journal of Vascular Surgery</i> , 1995, 21, 314-325.	1.1	197
168	951-73 Combined Antiplatelet Therapy without Anticoagulation: An Effective Alternative to Prevent Subacute Thrombosis After Coronary Stenting? A 3 Month Follow-up. <i>Journal of the American College of Cardiology</i> , 1995, 25, 197A.	2.8	14
169	Local Delivery of Vascular Endothelial Growth Factor Accelerates Reendothelialization and Attenuates Intimal Hyperplasia in Balloon-Injured Rat Carotid Artery. <i>Circulation</i> , 1995, 91, 2793-2801.	1.6	417
170	Recovery of Disturbed Endothelium-Dependent Flow in the Collateral-Perfused Rabbit Ischemic Hindlimb After Administration of Vascular Endothelial Growth Factor. <i>Circulation</i> , 1995, 91, 2802-2809.	1.6	106
171	Local Lesion-Related Factors and Restenosis After Coronary Angioplasty. <i>Circulation</i> , 1995, 91, 968-972.	1.6	42
172	Restenosis After Delayed Coronary Angioplasty of the Culprit Vessel in Patients With a Recent Myocardial Infarction Treated by Thrombolysis. <i>Circulation</i> , 1995, 91, 1410-1418.	1.6	26
173	Relation Between the Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene and Late Luminal Narrowing After Coronary Angioplasty. <i>Circulation</i> , 1995, 92, 296-299.	1.6	43
174	Accumulation of Fetal Fibronectin mRNAs After Balloon Denudation of Rabbit Arteries. <i>Circulation</i> , 1995, 92, 904-911.	1.6	38
175	Relation of Coronary Angioscopic Findings at Coronary Angioplasty to Angiographic Restenosis. <i>Circulation</i> , 1995, 92, 2473-2479.	1.6	48
176	Synergistic Effect of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor on Angiogenesis In Vivo. <i>Circulation</i> , 1995, 92, 365-371.	1.6	504
177	Effect of balloon inflation in angiographically normal coronary segments during coronary angiography: A quantitative angiographic study. <i>Catheterization and Cardiovascular Diagnosis</i> , 1994, 31, 116-121.	0.3	8
178	Use of human tissue specimens obtained by directional atherectomy to study restenosis. <i>Trends in Cardiovascular Medicine</i> , 1994, 4, 213-221.	4.9	22
179	Rotational atherectomy " An overview. <i>Developments in Cardiovascular Medicine</i> , 1994, , 353-366.	0.1	2
180	Coronary angiography " An inner view. <i>Developments in Cardiovascular Medicine</i> , 1994, , 369-381.	0.1	1

#	ARTICLE	IF	CITATIONS
181	Discordant results of visual and quantitative estimates of stenosis severity before and after coronary angioplasty. <i>Catheterization and Cardiovascular Diagnosis</i> , 1993, 28, 1-6.	0.3	64
182	Six-month quantitative angiographic follow-up of <50% diameter stenoses dilated during multilesion percutaneous transluminal coronary angioplasty. <i>American Journal of Cardiology</i> , 1993, 71, 1226-1229.	1.6	12
183	Relative prognostic value of clinical, exercise, and angiographic data after a first myocardial infarction. <i>Coronary Artery Disease</i> , 1993, 4, 727-736.	0.7	4
184	Dose-Response Curve of Angiographically Smooth Human Epicardial Vessel Segments to Intracoronary Injections of Isosorbide Dinitrate. <i>Journal of Cardiovascular Pharmacology</i> , 1992, 20, 473-478.	1.9	8
185	Clinical characteristics and angiographic follow-up of patients undergoing early or late repeat dilation for a first restenosis. <i>Journal of the American College of Cardiology</i> , 1992, 20, 845-848.	2.8	47
186	Percutaneous transluminal coronary rotary ablation with Rotablator (European experience). <i>American Journal of Cardiology</i> , 1992, 69, 470-474.	1.6	94
187	Prognostic value of changes in R-wave amplitude during exercise testing after a first acute myocardial infarction. <i>American Journal of Cardiology</i> , 1992, 70, 152-155.	1.6	3
188	Long term risk/benefit of PTCA of infarct related vessel. <i>Journal of the American College of Cardiology</i> , 1991, 17, A266.	2.8	2